Who are Dacomitinib (PF-00299804)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Capecitabine combined with Pyrotinib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dacomitinib-pf-00299804.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dacomitinib (PF-00299804) — Competitive Intelligence Brief

Dacomitinib (PF-00299804) (Dacomitinib (PF-00299804)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pan-HER tyrosine kinase inhibitor. Area: Oncology.

phase 3 Pan-HER tyrosine kinase inhibitor EGFR, HER2, HER4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dacomitinib (PF-00299804) (Dacomitinib (PF-00299804)) — Pfizer. Dacomitinib is a pan-HER tyrosine kinase inhibitor that irreversibly blocks EGFR, HER2, and HER4 signaling to inhibit tumor cell growth.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dacomitinib (PF-00299804) TARGET	Dacomitinib (PF-00299804)	Pfizer	phase 3	Pan-HER tyrosine kinase inhibitor	EGFR, HER2, HER4
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Capecitabine combined with Pyrotinib	Capecitabine combined with Pyrotinib	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Combination chemotherapy and tyrosine kinase inhibitor	Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pan-HER tyrosine kinase inhibitor class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dacomitinib (PF-00299804) — Competitive Intelligence Brief. https://druglandscape.com/ci/dacomitinib-pf-00299804. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab